Elotuzumab is a humanized IgG1 mAb directed selectively against SLAMF7, unable to induce direct or complement-mediated lysis of MM cells, as shown in vitro and by absence of clinical activity as single agent (82, 96) (Table 2). The gene discussed is SLAMF7; the disease is Miyoshi myopathy.